Patents by Inventor George Thom

George Thom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF
    Publication number: 20250263477
    Abstract: The invention provides antibodies that specifically bind human ?-synuclein with a high affinity and reduces ?-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating ?-synuclein antibodies, and methods of using ?-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.
    Type: Application
    Filed: January 16, 2025
    Publication date: August 21, 2025
    Inventors: Darren SCHOFIELD, Michael PERKINTON, Lorraine IRVING, George THOM
  • ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF
    Publication number: 20230331830
    Abstract: The invention provides antibodies that specifically bind human ?-synuclein with a high affinity and reduces ?-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating ?-synuclein antibodies, and methods of using ?-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.
    Type: Application
    Filed: January 20, 2023
    Publication date: October 19, 2023
    Inventors: Darren Schofield, Michael Perkinton, Lorraine Irving, George Thom
  • Antibodies to alpha-synuclein and uses thereof
    Patent number: 11560424
    Abstract: The invention provides antibodies that specifically bind human ?-synuclein with a high affinity and reduces ?-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating ?-synuclein antibodies, and methods of using ?-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: January 24, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Darren Schofield, Michael Perkinton, Lorraine Irving, George Thom
  • ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF
    Publication number: 20210179698
    Abstract: The invention provides antibodies that specifically bind human ?-synuclein with a high affinity and reduces ?-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating ?-synuclein antibodies, and methods of using ?-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.
    Type: Application
    Filed: December 3, 2020
    Publication date: June 17, 2021
    Inventors: Darren Schofield, Michael Perkinton, Lorraine Irving, George Thom
  • Antibodies to alpha-synuclein and uses thereof
    Patent number: 10889639
    Abstract: The invention provides antibodies that specifically bind human ?-synuclein with a high affinity and reduces ?-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating ?-synuclein antibodies, and methods of using ?-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: January 12, 2021
    Assignee: MedImmune Limited
    Inventors: Darren Schofield, Michael Perkinton, Lorraine Irving, George Thom
  • ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF
    Publication number: 20190276522
    Abstract: The invention provides antibodies that specifically bind human ?-synuclein with a high affinity and reduces ?-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating ?-synuclein antibodies, and methods of using ?-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.
    Type: Application
    Filed: October 25, 2018
    Publication date: September 12, 2019
    Inventors: Darren Schofield, Michael Perkinton, Lorraine Irving, George Thom
  • Antibodies to ?-synuclein and uses thereof
    Patent number: 10160800
    Abstract: The invention provides antibodies that specifically bind human ?-synuclein with a high affinity and reduces ?-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating ?-synuclein antibodies, and methods of using ?-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: December 25, 2018
    Assignee: MedImmune Limited
    Inventors: Darren Schofield, Michael Perkinton, Lorraine Irving, George Thom
  • ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF
    Publication number: 20180002411
    Abstract: The invention provides antibodies that specifically bind human ?-synuclein with a high affinity and reduces ?-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating ?-synuclein antibodies, and methods of using ?-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.
    Type: Application
    Filed: June 1, 2017
    Publication date: January 4, 2018
    Inventors: Darren Schofield, Michael Perkinton, Lorraine Irving, George Thom